CSC C06

Six Board directors, sixteen additional named Group/subsidiary executives and two Company Secretaries. The two executive directors also appear in the eighteen-person management roster and are not counted twice.

Subsidiary managing directors and functional Directors are not represented as CSC Board members. Outside-company CEO posts are kept separate.

Shang Zhiyang’s Deputy General Manager role started in April 2026; the source roster includes this post-year-end appointment.

Roles listed in ANNUAL REPORT 2026; current appointments are not independently verified.

Twenty registered/depository accounts, thirteen major-shareholder rows and eleven capital/distribution contexts at 16 June 2026. Eligible shares exclude 114,912,000 treasury shares; no subsidiary holdings.

Trustee, corporate-chain, direct and deemed interests can overlap. The TH chain and Ng Chwee Cheng/BOS chain are not additive beneficial holdings.

Share-register capital at 16 June differs from the 31 March primary statement share-capital amount of 94,089 thousand; preserve the different dates and reporting bases without inventing a transaction bridge.

Original UOB Kay Hian percentage 0.83% differs from independently rounded 0.84%, and Moomoo 0.76% differs from 0.77%, using the disclosed eligible-share denominator. Original percentages are retained. The top20 total 2,489,220,671 / 71.66% matches both the sum of printed percentages and the rounded aggregate share ratio.

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

The detailed notes contain 29 subsidiaries, four associate entities (including the 2TPC subsidiary), four joint ventures, two joint-operation entities and one 5% strategic FVOCI investment. The corporate structure adds three named entities without disclosed stakes: two UK associate-category entries and THAB PTP in other investments.

Subsidiary interests are Group effective equity: the THLFE chain is 55%, Wisescan 70%, and other subsidiaries 100%. Immediate held-by routes are shown without inventing their unprinted direct percentages.

The structure chart labels the four THL entities as joint operations, whereas detailed audited Note 11 classifies them as joint ventures. Detailed-note classification is used, with this original source conflict retained explicitly.

Six subsidiaries are expressly dormant; the Vietnam L&M entity is in the process of liquidation. Those statuses do not remove them from the disclosed entity census.

The Note 11 joint-venture table is headed Group ownership and prints 55% for all four entities, but the narrative expressly identifies THLFE’s direct stake as 55% and the Group effective interest as 30.25%. Both source presentations are retained and qualified; they are not four 55%-effective subsidiaries.

WB TOP3 is an associate at 19% because of significant influence through Board participation. 2TPC voting and policy participation vest in preference shares; the Group’s 20% preference interest confers significant influence.

NHCS and NH Singapore Biotechnology are joint operations with 49% Group interests; NHBT being wholly owned by NHCS does not make the Group interest 100%. THAB is a distinct 5% FVOCI investment with Nil fair value.

Note 11 dates the THL Max agreement and subscription to August/October 2024 while the current table has a prior-year dash and a first-year-incorporation auditor footnote. The FY2026 joint-venture reconciliation reclassifies 154 thousand from receivables and adds 310 thousand cash capital. The source dates, dash and classification are retained without asserting that all four entities were incorporated during FY2026.

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.